Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase I trial is studying the side effects and best dose of vorinostat when
given together with idarubicin in treating patients with relapsed or refractory leukemia or
myelodysplastic syndromes. Drugs used in chemotherapy, such as vorinostat and idarubicin,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Giving vorinostat together with idarubicin may
kill more cancer cells.